MKC-3946

Catalog No.S8286 Batch:S828601

Print

Technical Data

Formula

C21H20N2O3S
Molecular Weight 380.46 CAS No. 1093119-54-0
Solubility (25°C)* In vitro DMSO 38 mg/mL (99.87 mM)
Ethanol 3 mg/mL (7.88 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MKC3946 is a potent and soluble IRE1α endoribonuclease domain inhibitor which triggered modest growth inhibition in multiple myeloma cell lines, without toxicity in normal mononuclear cells.
Targets
IRE1α endoribonuclease [1]
In vitro MKC-3946 triggers modest growth inhibition in MM cell lines, without toxicity in normal mononuclear cells. Importantly, it significantly enhances cytotoxicity induced by bortezomib or 17-AAG, even in the presence of bone marrow stromal cells or exogenous IL-6. Both bortezomib and 17-AAG induce ER stress, evidenced by induction of XBP1s, which is blocked by MKC-3946. Apoptosis induced by these agents is enhanced by MKC-3946, associated with increased CHOP. MKC-3946 treatment does not inhibit IRE1α kinase function or binding of activated IRE1α to TRAF2 and downstream JNK signaling[1].
In vivo MKC-3946 inhibits XBP1 splicing in a model of ER stress in vivo, associated with significant growth inhibition of MM cells[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    RPMI 8226 cells

  • Concentrations

    2.5, 5, 10 μM

  • Incubation Time

    3 hours

  • Method

    RPMI 8226 cells are treated with or without Tm (5 μg/mL) in combination with MKC-3946 (0-10μM) for 3 hours. Total RNA is extracted; XBP1 and β-actin mRNA are evaluated by RT-PCR.
Animal Study:

[1]
  • Animal Models

    CB17 SCID mice

  • Dosages

    100 mg/kg

  • Administration

    i.p.

Selleck's MKC-3946 has been cited by 5 publications

Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer [ PLoS One, 2024, 19(6):e0304914] PubMed: 38935790
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death [ Nat Commun, 2023, 14(1):2132] PubMed: 37059720
Pharmacologic IRE1α kinase inhibition alleviates aortic dissection by decreasing vascular smooth muscle cells apoptosis [ Int J Biol Sci, 2022, 18(3):1053-1064] PubMed: 35173538
On the origin of metastases: Induction of pro-metastatic states after impending cell death via ER stress, reprogramming, and a cytokine storm [ Cell Rep, 2022, 38(10):110490] PubMed: 35263600
Rapid Death of Follicular B Cells and Burkitt Lymphoma Cells Effectuated by Xbp1s [ J Immunol, 2020, 204(12):3236-3247] PubMed: 32376649

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.